Cargando…

Managing Adverse Events Associated with Dinutuximab Beta Treatment in Patients with High-Risk Neuroblastoma: Practical Guidance

Neuroblastoma is the most common extracranial solid tumour in children, accounting for 15% of all paediatric cancer deaths. High-risk neuroblastoma is a particularly challenging-to-treat form of disease that requires multimodality treatment, consisting of chemotherapy, surgery, high-dose chemotherap...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barone, Giuseppe, Barry, Ailish, Bautista, Francisco, Brichard, Bénédicte, Defachelles, Anne-Sophie, Herd, Fiona, Manzitti, Carla, Reinhardt, Dirk, Rubio, Pedro M., Wieczorek, Aleksandra, van Noesel, Max M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Therapy in Practice
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563639/ https://www.ncbi.nlm.nih.gov/pubmed/34541620 http://dx.doi.org/10.1007/s40272-021-00469-9

Ejemplares similares

Dinutuximab beta for neuroblastoma
Publicado: (2020)

Clinical Phenotype and Management of Severe Neurotoxicity Observed in Patients with Neuroblastoma Treated with Dinutuximab Beta in Clinical Trials
por: Wieczorek, Aleksandra, et al.
Publicado: (2022)

Dinutuximab beta combined with chemotherapy in patients with relapsed or refractory neuroblastoma
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
por: Ehlert, Karoline, et al.
Publicado: (2020)

Early Use of Dinutuximab Beta in Patients with High-Risk Neuroblastoma
por: Spasov, Neofit, et al.
Publicado: (2021)

Dinutuximab Beta Maintenance Therapy in Patients with High-Risk Neuroblastoma in First-Line and Refractory/Relapsed Settings—Real-World Data
por: Wieczorek, Aleksandra, et al.
Publicado: (2023)

Multidisciplinary Clinical Care in the Management of Patients Receiving Anti-GD2 Immunotherapy for High-Risk Neuroblastoma
por: Cabral, Jennifer, et al.
Publicado: (2022)

Clinical Presentation and Management of a Dinutuximab Beta Extravasation in a Patient with Neuroblastoma
por: Launspach, Michael, et al.
Publicado: (2021)

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance
por: Lorusso, Domenica, et al.
Publicado: (2020)

Recent Evidence-Based Clinical Guide for the Use of Dinutuximab Beta in Pediatric Patients with Neuroblastoma
por: Balaguer, Julia, et al.
Publicado: (2022)

Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy
por: Keyel, Michelle E, et al.
Publicado: (2018)

Dinutuximab Beta in Children with High-Risk Neuroblastoma: Experience from a Single Center in Croatia
por: Giljević, Jasminka Stepan, et al.
Publicado: (2022)

Treatment of High-Risk Neuroblastoma with Dinutuximab and Chemotherapy Administered in all Cycles of Induction
por: Cupit-Link, Margaret, et al.
Publicado: (2023)

Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava
por: Achbergerová, Monika, et al.
Publicado: (2022)

Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy
por: Cicek, Filiz, et al.
Publicado: (2020)

Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience
por: Olgun, Nur, et al.
Publicado: (2022)

Quantification of total dinutuximab concentrations in neuroblastoma patients with liquid chromatography tandem mass spectrometry
por: El Amrani, Mohsin, et al.
Publicado: (2018)

Mechanisms, Characteristics, and Treatment of Neuropathic Pain and Peripheral Neuropathy Associated with Dinutuximab in Neuroblastoma Patients
por: Mastrangelo, Stefano, et al.
Publicado: (2021)

Pruritus in Pregnancy
por: Stefaniak, Aleksandra A., et al.
Publicado: (2022)

Review of the home care programmes for respiratory syncytial virus (RSV) prophylaxis in Ireland and The Netherlands
por: Whelan, Barbara, et al.
Publicado: (2016)

Investigation of the Role of Dinutuximab Beta-Based Immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 Trial (HR-NBL1)
por: Ladenstein, Ruth, et al.
Publicado: (2020)

GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma
por: Zirngibl, Felix, et al.
Publicado: (2021)

The Immunocytokine FAP-IL-2v Enhances Anti-Neuroblastoma Efficacy of the Anti-GD(2) Antibody Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2022)

Local delivery of dinutuximab from lyophilized silk fibroin foams for treatment of an orthotopic neuroblastoma model
por: Ornell, Kimberly J., et al.
Publicado: (2020)

Effect and Tolerance of N5 and N6 Chemotherapy Cycles in Combination with Dinutuximab Beta in Relapsed High-Risk Neuroblastoma Patients Who Failed at Least One Second-Line Therapy
por: Lode, Holger N., et al.
Publicado: (2023)

Combined Blockade of TIGIT and PD-L1 Enhances Anti-Neuroblastoma Efficacy of GD2-Directed Immunotherapy with Dinutuximab Beta
por: Siebert, Nikolai, et al.
Publicado: (2023)

Chemotherapeutics Used for High-Risk Neuroblastoma Therapy Improve the Efficacy of Anti-GD2 Antibody Dinutuximab Beta in Preclinical Spheroid Models
por: Troschke-Meurer, Sascha, et al.
Publicado: (2023)

Multimodal Therapy with Consolidating Haploidentical Stem Cell Transplantation and Dinutuximab Beta for Patients with High-Risk Neuroblastoma and Central Nervous System Relapse
por: Flaadt, Tim, et al.
Publicado: (2023)

CD47-SIRPα Checkpoint Inhibition Enhances Neutrophil-Mediated Killing of Dinutuximab-Opsonized Neuroblastoma Cells
por: Martínez-Sanz, Paula, et al.
Publicado: (2021)

G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment
por: Martinez Sanz, Paula, et al.
Publicado: (2021)

Essentials for Selecting Antimicrobial Therapy for Intra-Abdominal Infections
por: Blot, Stijn, et al.
Publicado: (2012)

Managing the Child with Severe Primary Insulin-Like Growth Factor-1 Deficiency (IGFD): IGFD Diagnosis and Management
por: Cohen, Jay, et al.
Publicado: (2014)

Managing Therapeutic Competition in Patients with Heart Failure, Lower Urinary Tract Symptoms and Incontinence
por: Tannenbaum, Cara, et al.
Publicado: (2013)

Diagnosing and Managing Postherpetic Neuralgia
por: Nalamachu, Srinivas, et al.
Publicado: (2012)

Management of Functional Constipation in Children: Therapy in Practice
por: Koppen, Ilan J. N., et al.
Publicado: (2015)

What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion
por: Vellucci, R., et al.
Publicado: (2016)

Efficacy of Lifestyle Changes in Subjects with Non-Alcoholic Liver Steatosis and Metabolic Syndrome May Be Improved with an Antioxidant Nutraceutical: A Controlled Clinical Study
por: Sorrentino, Gianpaolo, et al.
Publicado: (2015)

Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2015)

Modifying Antiretroviral Therapy in Virologically Suppressed HIV-1-Infected Patients
por: Collins, Sean E., et al.
Publicado: (2015)

Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts
por: Berger, Thomas, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_4bk469spc808qah1ombssaom8o